Bayer in Venture With Gene-Editing Startup

Christopher Alessi and Jonathan Rockoff, The Wall Street Journal, December 20th, 2015.

Germany based Bayer AG has partnered with CRISPR Therapeutics AG to develop gene editing therapies for conditions such as hemophilia, infant heart disease, and Stargardt blindness.  CRISPR Therapeutics was founded by Dr. Emmanuelle Charpentier, co-author of the breakthrough 2012 CRISPR Science paper with Dr. Jennifer Doudna. The deal is worth $300 million over five years with Bayer acquiring a $35 million stake in CRISPR Therapeutics.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply